Anavex Life Sciences Corp (AVXL)

[Rubyred77]

Take the lead on cancer to find a cure for Alzheimer's disease (News Release)

Research
Issued by: ICM Institute
08/05/2018
Releases

Anavex Life Sciences Announces New Data Identifying the Response to Biomarker Therapy in Alzheimer's Disease Patients Treated with ANAVEX®2-73 Experimental Drugs at the Alzheimer's Association's 2018 International Conference (AAIC)
An analysis of over 33,000 identified genetic variants that can lead to the development of a precision drug.
Approach to research and treatment of Alzheimer's disease
The study identified 80% of participants as ANAVEX®2-73 respondents.
Notes for Improvement of Cognition (MMSE) and Activities of Daily Living (ADCS-ADL)
The data will inform recruitment for advanced clinical trials ANAVEX®2-73.

Dr. Harald Hampel, professor at the Sorbonne University in Paris, explains that the experimental drug, Anavex 2-73, a candidate in precision medicine from the specialty pharmaceutical company Anavex Life Sciences Corp. activates the Sigma-1 receptor. An experimental drug presented last week at the 2018 International Conference of the Alzheimer's Association in Chicago (AAIC) which takes place every year.
Read the rest of the press release: Towards a treatment for Alzheimer's disease
Press contact
Florence Majri
Sorbonne University Research Project Coordinator
[e-mail]
[e-mail]